Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market poised to grow substantially during the Forecast Period 2023-2030

by

The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is estimated to be valued at US$ 9,730.72 million in 2027 and is expected to exhibit a CAGR of 31.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive, and fatal disease characterized by the build-up of abnormal deposits of misfolded transthyretin protein (TTR) in the heart. These deposits cause the heart muscle to thicken and stiffen over time, resulting in heart failure. Currently available treatments for ATTR-CM include tafamidis which helps to stabilize the TTR tetramer and thereby prevents amyloid formation.

Market key trends:
One of the key trends in the ATTR-CM treatment market is the strong pipeline of drugs. There are several drug candidates in various stages of clinical trials that offer better efficacy and convenience over existing therapies. For instance, patisiran by Alnylam Pharmaceuticals is an RNAi therapeutic targeting TTR mRNA. In clinical trials, it has demonstrated significant reduction in serum TTR levels with continued treatment. If approved, it can capture a sizable share of the ATTR-CM treatment market.

Segment Analysis

The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is segmented into wild-type and hereditary ATTR-CM. The hereditary ATTR-CM segment dominated the market in 2019 owing to higher prevalence rate along with availability of approved therapies for hereditary ATTR-CM treatment.

Key Takeaways

The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31.1% over the forecast period, due to increasing approval of novel therapies and rising diagnosis rate.

The North American region dominated the global market in 2019 owing to early approval of therapies and presence of key pharmaceutical companies. However, Asia Pacific is expected to grow at the fastest rate during the forecast period.

Key players operating in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market are Pfizer Inc., GlaxoSmithKline Plc., Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it